期刊文献+

波生坦治疗特发性肺动脉高压的临床研究 被引量:2

Clinical Study on Bosentan in Treatment of Idiopathic Pulmonary Arterial Hypertension
下载PDF
导出
摘要 目的观察波生坦治疗特发性肺动脉高压的临床疗效及安全性。方法选择我院收治的15例特发性肺动脉高压患者,口服波生坦进行治疗,对比治疗前后患者的各项指标变化情况。结果治疗后,患者心功能得到了明显改善;6WMD、NT-proBNP、LVEDD、mPAP等指标均较治疗前明显改善(P<0.05);患者血常规及肝肾功能检查结果均无明显变化(P>0.05)。结论波生坦是治疗特发性动脉高血压的安全有效的药物,值得向临床推荐。 Objective To observe the efficacy of Bosentan in idiopathic pulmonary hypertension(IPAH).Methods 15 patients with IPAH were treated with Bosentan,to compare the changes of indicator.Results After treatment,the patients’ cardiac function has been significantly improved,and other indicators had been improved significantly(P0.05).Conclusion Bosentan is safe and effective in treatment of IPAH,and it is worthy of clinical recommendations.
出处 《中国医药指南》 2012年第34期405-407,共3页 Guide of China Medicine
关键词 波生坦 特发性肺动脉高压 临床分析 Bosentan Idiopathic pulmonary hypertension Clinical analysis
  • 相关文献

参考文献6

二级参考文献69

  • 1荆志成,徐希奇.肺动脉高压现代分类和诊断策略[J].中华心血管病杂志,2004,32(12):1160-1162. 被引量:40
  • 2荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 3程显声.特发性肺动脉高压的诊断[J].中国循环杂志,2006,21(6):478-480. 被引量:8
  • 4荆志成.我国肺动脉高压专家共识阐释[J].中国实用内科杂志,2007,27(4):246-249. 被引量:53
  • 5D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension.Results from a national prospective registry[J]. Ann Intern Med, 1991, 115(5): 343-349.
  • 6Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence based clinical practice guidelines[J]. Chest, 2004, 126 (1 Supp 1): 7-10.
  • 7程显声,陆慰萱,王辰.肺循环病学[M].北京:人民卫生出版社,2007.206.
  • 8The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension[J].Eur Heart J, 2004, 25(24): 2243-2278.
  • 9Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test[J]. Am J Respir Crit Care Med, 200a, 167(9) : 1287.
  • 10Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient [J]. Vase Health Risk Manag, 2009, 5: 607- 619.

共引文献278

同被引文献9

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部